RVLP.Q Stock Overview
A specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
RVL Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.006 |
| 52 Week Low | US$0.000001 |
| Beta | 27.76 |
| 11 Month Change | 9,900.00% |
| 3 Month Change | 9,900.00% |
| 1 Year Change | -97.73% |
| 33 Year Change | -99.99% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 16
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts
May 13RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares
May 12RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt
Apr 20Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?
Jan 05RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M
Oct 18RVL Pharmaceuticals: Chapter 2 - A Developing Quandary
Sep 22RVL Pharma in pact with Revision Skincare to broaden access to products
Aug 30GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M
Aug 11RVL Pharma posts preliminary 42% sales growth for eye treatment
Jul 07RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt
Jul 04RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture
Jun 15New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)
Apr 01RVL Pharmaceuticals: A Makeover For An Ugly Duckling
Mar 30Osmotica: A Different Breed Of Cat
Dec 14Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt
Aug 20Osmotica: Paring Down, Focusing On UPNEEQ
Jul 16Shareholder Returns
| RVLP.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 9,900.0% | 1.6% | 2.2% |
| 1Y | -97.7% | 10.0% | 31.7% |
Return vs Industry: RVLP.Q underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: RVLP.Q underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| RVLP.Q volatility | |
|---|---|
| RVLP.Q Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine RVLP.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 125 | Brian Markison | www.rvlpharma.com |
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.
RVL Pharmaceuticals plc Fundamentals Summary
| RVLP.Q fundamental statistics | |
|---|---|
| Market cap | US$111.00 |
| Earnings (TTM) | -US$68.27m |
| Revenue (TTM) | US$36.92m |
0.0x
P/S Ratio0.0x
P/E RatioIs RVLP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVLP.Q income statement (TTM) | |
|---|---|
| Revenue | US$36.92m |
| Cost of Revenue | US$6.53m |
| Gross Profit | US$30.39m |
| Other Expenses | US$98.66m |
| Earnings | -US$68.27m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.61 |
| Gross Margin | 82.31% |
| Net Profit Margin | -184.91% |
| Debt/Equity Ratio | 353.7% |
How did RVLP.Q perform over the long term?
See historical performance and comparison